tislelizumab + bevacizumab + oxaliplatin + fluorouracil + leucovorin

This combination regimen is a chemo-immunotherapy approach being investigated for the first-line treatment of advanced hepatocellular carcinoma (HCC). It integrates the PD-1 inhibitor tislelizumab, the anti-VEGF monoclonal antibody bevacizumab, and the FOLFOX4 chemotherapy backbone (comprising oxaliplatin, 5-fluorouracil, and leucovorin). The rationale behind this five-drug combination is to achieve a synergistic therapeutic effect by simultaneously restoring T-cell mediated anti-tumor immunity, inhibiting tumor angiogenesis, and inducing direct cytotoxic damage to cancer cells. Bevacizumab's role in normalizing the tumor microenvironment is thought to enhance the infiltration and activity of immune cells activated by tislelizumab, while the FOLFOX regimen provides systemic control and potentially increases the release of tumor-associated antigens. This specific protocol is primarily associated with clinical research conducted at West China Hospital, Sichuan University.

Other names

Tislelizumab + Bevacizumab + FOLFOXTislelizumab + Bevacizumab + FOLFOX4